Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.47 |
| ▸ | DPYD | Q12882 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | UBE2N | P61088 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | GFER | P55789 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | LPO | P22079 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21345242 | 0.83 | KDM3B (0.47) | KDM3BDPYDKMT2ATDP1MEN1 | |
| SCHEMBL1916591 | 0.80 | DPYD (0.63) | DPYDGAAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL28393916 | 0.72 | KDM3B (0.39) | KDM3BDPYDKMT2ATDP1MEN1 | |
| SCHEMBL10509279 | 0.68 | — | — | |
| SCHEMBL3321070 | 0.68 | — | — | |
| SCHEMBL25418259 | 0.68 | ATAD2 (0.60) | KDM3BKMT2ATDP1MEN1RXFP1 | |
| SCHEMBL1404492 | 0.68 | — | — | |
| SCHEMBL11739894 | 0.68 | — | — | |
| SCHEMBL25450 | 0.68 | — | — | |
| SCHEMBL5559308 | 0.66 | ATAD2 (0.53) | KDM3BDPYDKMT2ATDP1UBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727976-B2 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7053076-B2 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060030551-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. | 2006-02-09 | — | — | US | disclosed |
| US-20030130246-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003020214-A2 | BILE-ACID DERIVED COMPOUNDS FOR ENHANCING ORAL ABSORPTION AND SYSTEMIC BIOAVAILABILITY OF DRUGS | XENOPORT, INC. (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130246-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | SLC10A2, ABCB11, SLC10A1 | KDM3B 4748/4885DPYD 1209/4885KMT2A 4785/4885 |
| US-20060030551-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | SLC10A2, ABCB11, SLC10A1 | KDM3B 4748/4885DPYD 1209/4885KMT2A 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.